Journal
MICROSCOPY RESEARCH AND TECHNIQUE
Volume 76, Issue 9, Pages 936-941Publisher
WILEY-BLACKWELL
DOI: 10.1002/jemt.22251
Keywords
postsynthesis etching; mesoporous nanostructures; iron oxide nanoparticles; gene delivery
Categories
Funding
- National Science Foundation [CBET-0854465, CBET-0854414, DMR-0847758]
- National Institutes of Health [5R01HL092526-02, 1R21EB015190-01A1, 4R03AR056848-03]
- Department of Defense Peer Reviewed Medical Research Program [W81XWH-12-1-0384]
- Oklahoma Center for the Advancement of Science and Technology [HR11-006]
- Oklahoma Center for Adult Stem Cell Research [434003]
- Direct For Mathematical & Physical Scien
- Division Of Materials Research [847758] Funding Source: National Science Foundation
- Div Of Chem, Bioeng, Env, & Transp Sys
- Directorate For Engineering [0854465] Funding Source: National Science Foundation
- Div Of Chem, Bioeng, Env, & Transp Sys
- Directorate For Engineering [0854414] Funding Source: National Science Foundation
Ask authors/readers for more resources
Novel monodisperse mesoporous iron oxide nanoparticles (m-IONPs) were synthesized by a postsynthesis etching approach and characterized by electron microscopy. In this approach, solid iron oxide nanoparticles (s-IONPs) were first prepared following a solvothermal method, and then etched anisotropically by polyacrylic acid to form the mesoporous nanostructures. MTT cytotoxicity assay demonstrated that the m-IONPs have good biocompatibility with mesenchymal stem cells (MSCs). Owing to their mesoporous structure and good biocompatibility, these monodisperse m-IONPs were used as a nonviral vector for the delivery of a gene of vascular endothelial growth factor (VEGF) tagged with a green fluorescence protein (GFP) into the hard-to-transfect stem cells. Successful gene delivery and transfection were verified by detecting the GFP fluorescence from MSCs using fluorescence microscopy. Our results illustrated that the m-IONPs synthesized in this work can serve as a potential nonviral carrier in gene therapy where stem cells should be first transfected and then implanted into disease sites for disease treatment. Microsc. Res. Tech. 76:936-941, 2013. (c) 2013 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available